Drug reference

deflazacort

corticosteroid · glucocorticoid, antiinflammatory, immunosuppressant

corticosteroidglucocorticoid, antiinflammatory, immunosuppressant

CDSCO approved

EXCRETION

—

not curated

INTERACTIONS

12 major

incl. contraindicated

PREGNANCY

—

not curated

Top interactionssee all 12 →

Live Attenuated VaccinesContraindicatedDatabase
AdalimumabSevereDatabaseDDInter
AmprenavirSevereDatabaseDDInter
ApalutamideSevereDatabaseDDInter

Mechanism

Deflazacort penetrates cells and binds to a high affinity cytoplasmic receptor protein. This complex migrates into the nucleus and binds to glucocorticoid response elements (GRE) on chromatin, regulating protein synthesis. It is a glucocorticoid with antiinflammatory and immunosuppressive effects, lacking mineralocorticoid activity.

Indications

inflammatory disordersimmunological disorders

Dosing

Adult: 60–120 mg/day initially, 6–18 mg/day for maintenance.

Pharmacokinetics

Half-life

biological t½ 12–36 hours

Contraindications

peptic ulcer
diabetes mellitus
hypertension
viral infections
fungal infections
tuberculosis
other infections
osteoporosis
herpes simplex keratitis
psychosis
epilepsy
congestive heart failure
renal failure

Side effects

Serious

less growth retardation in children

Drug interactions

Live Attenuated Vaccines

Contraindicated

Database

Risk of disseminated infection from the vaccine strain. Reduced vaccine efficacy.

Avoid live attenuated vaccines during deflazacort therapy (especially at immunosuppressive doses) and for a period after discontinuation. Inactivated vaccines are generally safe but may have reduced efficacy.

Adalimumab

Severe

Database

Drug interaction classified as: synergy.

Source: DDInter

Amprenavir

Severe

Database

Drug interaction classified as: metabolism

Source: DDInter

Apalutamide

Severe